## Lei Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4599852/publications.pdf Version: 2024-02-01



Let Lui

#	Article	IF	CITATIONS
1	Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. Cell, 2019, 179, 1483-1498.e22.	13.5	120
2	Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors. Neuron, 2021, 109, 3402-3420.e9.	3.8	75
3	A cellular complex of BACE1 and Î <sup>3</sup> -secretase sequentially generates AÎ <sup>2</sup> from its full-length precursor. Journal of Cell Biology, 2019, 218, 644-663.	2.3	57
4	Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 121.	2.4	46
5	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nature Communications, 2020, 11, 6024.	5.8	43
6	The FAM3 superfamily member ILEI ameliorates Alzheimer's disease-like pathology by destabilizing the penultimate amyloid-l² precursor. Nature Communications, 2014, 5, 3917.	5.8	37
7	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
8	Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate Î <sup>3</sup> -secretase function in generating Alzheimer-causing AÎ <sup>2</sup> peptides. Journal of Biological Chemistry, 2021, 296, 100393.	1.6	22
9	Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson's disease. Cell Reports, 2021, 36, 109333.	2.9	22
10	Neuronal expression of ILEI/FAM3C and its reduction in Alzheimer's disease. Neuroscience, 2016, 330, 236-246.	1.1	21
11	Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 79-96.	0.4	21
12	An ultraâ€sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma. Alzheimer's and Dementia, 2022, 18, 1186-1202.	0.4	18
13	Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its halfâ€life. Alzheimer's and Dementia, 2019, 15, 1183-1194.	0.4	17
14	Brain region-specific susceptibility of Lewy body pathology in synucleinopathies is governed by α-synuclein conformations. Acta Neuropathologica, 2022, 143, 453-469.	3.9	14
15	Ageâ€related modulation of γâ€secretase activity in nonâ€human primate brains. Journal of Neurochemistry, 2012, 123, 21-28.	2.1	12
16	Dilysine retrieval signalâ€containing p24 proteins collaborate in inhibiting γâ€cleavage of amyloid precursor protein. Journal of Neurochemistry, 2010, 115, 771-781.	2.1	11
17	Verubecestat for Prodromal Alzheimer's Disease. New England Journal of Medicine, 2019, 381, 388-389	13.9	10
18	Aβ oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. Neurobiology of Disease, 2022, 172, 105816.	2.1	8

Lei Liu

#	Article	IF	CITATIONS
19	Pathogenic Mechanisms of Cytosolic and Membrane-Enriched α-Synuclein Converge on Fatty Acid Homeostasis. Journal of Neuroscience, 2022, 42, 2116-2130.	1.7	7
20	A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer's disease brain. Brain, 2022, , .	3.7	7
21	Preâ€synaptic localization of the γâ€secretaseâ€inhibiting protein p24α <sub>2</sub> in the mammalian brain. Journal of Neurochemistry, 2015, 133, 422-431.	2.1	6
22	Extracellular Release of ILEI/FAM3C and Amyloid-β Is Associated with the Activation of Distinct Synapse Subpopulations. Journal of Alzheimer's Disease, 2021, 80, 159-174.	1.2	5
23	Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy. Npj Parkinson's Disease, 2022, 8, .	2.5	5
24	A novel V272D presenilin mutation associated with logopenia, disorientation, and apraxia in an autosomal-dominant Alzheimer's disease family. Neurobiology of Aging, 2020, 85, 154.e5-154.e7.	1.5	4
25	Generation and application of semi-synthetic p-Tau181 calibrator for immunoassay calibration. Biochemical and Biophysical Research Communications, 2022, 611, 85-90.	1.0	4
26	Immunohistochemical detection of the delayed formation of nonfibrillar large amyloidâ€Î² aggregates. Genes To Cells, 2016, 21, 200-211.	0.5	3
27	Discovery of aryl aminothiazole Î <sup>3</sup> -secretase modulators with novel effects on amyloid Î <sup>2</sup> -peptide production. Bioorganic and Medicinal Chemistry Letters, 2021, 54, 128446.	1.0	3
28	Predicting development of AD clinical symptoms and their progression through a collection of novel plasma Al² immunoassays. Alzheimer's and Dementia, 2020, 16, e043670.	0.4	1
29	P3-025: P24α2 INTERACTS WITH GAMMA-SECRETASE COMPLEX AT PRESYNAPTIC TERMINALS. , 2014, 10, P636-P636.		0

30 FAM3C in Alzheimer's disease. , 2020, , 293-307.

0